TAmiRNA is proud to announce its participation at the upcoming European Bone and Joint Infection Society (EBJIS) Meeting 2025 in Ferrara, Italy.
On Thursday, September 11, 2025 at 11:00 (Sala Emilia), Dr. Bernhard JH Frank will present groundbreaking new results from a collaborative study conducted with the Orthopaedic Hospital Speising and Dr. Jochen G. Hofstätter. The presentation is entitled:
“Synovial fluid microRNA biomarkers enable accurate diagnosis of hip and knee periprosthetic joint infections.”
Synovial fluid microRNA biomarkers for accurate PJI diagnosis
Periprosthetic joint infection (PJI) is one of the most severe complications after hip and knee replacement surgery. Accurate and timely diagnosis remains a clinical challenge due to limited sensitivity and specificity of current diagnostic methods.
In this study, TAmiRNA and its clinical partners employed small RNA-sequencing and RT-qPCR validation to profile synovial fluid microRNAs from patients with suspected bone and joint infections. The results demonstrate that microRNA signatures in synovial fluid can distinguish PJI from aseptic failure with >97% diagnostic accuracy.
This represents a major advance in biomarker discovery for orthopedic infections, offering a path towards more sensitive and specific molecular diagnostics.
A step forward in biomarker discovery
These findings highlight the potential of liquid biopsy approaches and molecular biomarker panels in orthopedics. MicroRNA-based assays could complement existing microbiological and immunological tests, enabling:
- Earlier and more reliable detection of periprosthetic joint infections
- Improved patient management and treatment decision-making
- Reduced healthcare costs by preventing unnecessary revision surgeries
By leveraging its expertise in microRNA biomarker discovery, RNA sequencing, and quantitative RT-qPCR assay development, TAmiRNA is driving innovation in the field of bone and joint infection diagnostics.
